Introduction
Fragile X syndrome (FXS), the most common form of inherited intellectual disability (Santoro et al., 2012) , is characterized by synaptic immaturity, cognitive deficits (Koekkoek et al., 2005) , and autistic-like behavior (Sabaratnam et al., 2003) . The disorder is typically caused by an expansion of an untranslated CGG repeat in the 5' untranslated region of the X-linked gene fragile X mental retardation 1 (FMR1; Verkerk et al., 1991) . This triplet expansion leads to DNA methylation of FMR1 and transcriptional shutdown of the gene. The loss of the fragile X mental retardation protein (FMRP), an RNA-binding protein, causes dysregulation of the translation of dendritic mRNAs (Ashley et al., 1993; Darnell and Klann, 2013) . FMRP represses translation probably by interacting with a specific subset of mRNAs, directly binding to the ribosome with high affinity, and thereby precluding the binding of tRNA and translation elongation factors on the ribosome (Chen et al., 2014) . The key functional role of the binding of FMRP to RNA is supported by the evidence that a missense mutation in the KH2 domain (Ile304Asn) of human FMRP abolishes its binding to polyribosome and leads to a severe form of FXS (Siomi et al., 1994) .
Signal processing at synapses is dramatically altered due to the lack of FMRP, resulting in an impaired ability in synaptogenesis, synaptic maturation, and synaptic plasticity to meet cognitive demands (Nelson and Alkon, 2015) and behavioral control. The most compelling is the evidence involving the metabotropic glutamate receptor 5 (mGluR5; Bhattacharya and Klann, 2012) , based on the observation of an abnormally enhanced mGluR5-dependent long-term depression in fragile X mice (Huber et al., 2002) . The leading 'mGluR theory of FXS indicates that overactive mGluR5 signaling, normally balanced by FMRP, underlies much of the brain pathology of FXS (Santoro et al., 2012; Hajós, 2014) . Drug development for the treatment of FXS thus has been JPET #231100 page 6 focused on achieving this balance by reducing the mGluR5 hyperactivity in the brain.
Consistently, genetic reduction of mGluR5 expression or pharmacologic mGluR5 antagonism has been reported to correct many FXS phenotypes in fragile X mice (Huber et al., 2002; Hajós, 2014) .
We have found that chronic activation of PKCε in the hippocampus can rescue synapses and spatial cognition, as well as other FXS phenotypes, in adult fragile X mice after the disorder has established (Sun et al., 2014) . The downside of the late-onset treatment is that the therapy may miss a critical period of youth, important in age-related socio-cognitive and behavioral development. It is also not clear whether the observed therapeutic effects involve downregulation of the mGluR5 in the hippocampus. If the syndrome is a lasting consequence of brain development with deficit in synaptic maturation, it is possible that early intervention with agents that facilitate synaptic maturation could achieve a better outcome, unfolding full potential of therapeutics. This is highly achievable, considering the evidence that newborn screening for FXS is technically feasible (Tassone, 2014) . In this study, we, therefore, evaluate therapeutic potential of a PKCε activator on synapses, cognitive function, and other FXS phenotypes, including mGluR5 expression in the hippocampus of young fragile X mice.
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Materials and Methods
Animals and drug treatment
Two types of mice (male, The Jackson Laboratories, ME, USA; 9-10/group; at an age of close to 3 weeks when obtained) were used: FVB.129P2-Pde6b
+ Tyr c-ch Fmr1 tm1Cgr /J (fragile X mice) and FVB.129P2-Pde6b + Tyr c-ch /AntJ (age-matched wild-type controls). These mice do not suffer from blindness. They were housed in a temperature-controlled (20-24°C) room, allowed free access to food and water, and kept on a 12-hour light/dark cycle.
All mice were randomly assigned to different groups. Bryostatin-1 was administered (20 μg/m 2 , tail i.v., 2 doses/week for 6 weeks), starting at an age of close to 4 weeks (26-27 days).
The treatment would catch the last week or so in brain development (A month in a mouse with a lifespan of 2 years is roughly equal to 3.3 years of brain development in humans; Sengupta, 2013) before FXS phenotypes are established in the fragile X mice (Bhattacharya and Klann, 2012) . Although synaptogenesis and synaptic maturation occur throughout a mammalian lifespan, the mouse brain development is anatomically complete at about 5 weeks of age, when all FXS phenotypes are established in the fragile X mice (Michalon et al., 2012; Bhattacharya and Klann, 2012) . The age would roughly correspond to mid-adolescence (~15 years of age) in human in term of synaptic maturation in the prefrontal cortex (Huttenlocher and Dabholkar, 1997) . The same behavioral training procedures were performed in all animal groups in the study, so that differences in observed results would indeed reflect impacts of drug treatments.
The dose was based on our preliminary dose-response studies that smaller doses were not effective against disorders-induced synaptic and cognitive impairments. Non-treated groups received the same volume of vehicle at the same frequency. Synaptic and memory functions and other phenotypic features were evaluated 9 days after the last dose.
This article has not been copyedited and formatted. The final version may differ from this version. Tissue preparation for confocal microscopy Animals were deeply anesthetized with sodium pentobarbital (120 mg/kg, i.p.) and perfused through the heart with phosphate buffered saline (PBS) for <4 min at room temperature and then with 4% paraformaldehyde in PBS (≈ 40 ml) to remove any negative impact of hypothermia on dendritic spines (Kirov et al., 2004) . Brains were then kept in 4% paraformaldehyde in PBS for 10 min at 4°C and stored in PBS at 4°C. Right dorsal hippocampi were sectioned with a vibratome (Leica VT1200S) into 200 μ m thickness and kept in series in PBC at 4°C for 3-D reconstruction.
3D reconstruction analysis of dendritic spine morphology on dendritic shafts
The tips of glass electrodes, prepared for electrophysiological experiments, were immersed for 10s in 5% (w/v) 1,1'-Dioctadecyl-3,3,3',3'-Tetramethylindocarbocyanine Perchlorate (DiI) in dichloromethane (Sigma-Aldrich) and air-dried at room temperature for 1 hour (twice). The tips of DiI-coated electrodes were inserted, broken, and left in the strata oriens of CA1 area of hippocampal sections at 200 μ m thickness (3-4 electrode tips/slice). After maintenance in PBS at 4°C overnight, the hippocampal sections were resectioned to 7 μ m thickness and kept in PBS at 4°C. In case that DiI was not well diffused along dendritic shafts, the 7-μm thickness sections in PBS were changed from 4°C to room temperature. At each time of confocal scanning, only one section was freshly mounted on a silane-coated microscope slide (SilanatedTM Slides, KD Medical, Columbia, MD), using 4% paraformaldehyde in PBS as a mounting medium.
Dendrites were imaged by a Zeiss Axio Observer Z1 microscope equipped with a 710-confocal scanning microscopy (>510 nm/568 nm; excitation/emission) using 100x Plan-APO This article has not been copyedited and formatted. The final version may differ from this version. projections from dendritic shafts at 0.2-3 μm length were classified as dendritic spines. Dendritic spines with head to neck diameter ratio (Neck Ratio) greater than 1.1 were either considered as thin or mushroom spines (see below). Spines that were not met the Neck Ratio value (head to neck diameter ratio of greater than 1.1) and had a length of spine to head diameter (Thin Ratio) above 2.5 were automatically classified as thin, otherwise as stubby. Spines that met the Neck Ratio value and had a head diameter (Mushroom Size) equal or greater than 600 nm (Sorra and Harris, 2000) were automatically labeled as mushroom, otherwise as stubby. Filopodia were identified manually (long profiles without enlarged heads) from the projection structures that was longer than dendritic spines and did not have enlarged heads.
Immunohistochemistry
While histochemical levels of PSD-95 or synaptophysin have been found to correspond well This article has not been copyedited and formatted. The final version may differ from this version. with those detected at the biochemical levels (Glantz et al., 2007; Horling et al., 2015) , Western blots measure the total protein levels in the tissue and may have results different from histochemistry at a single structure or cell level, due to protein expression or transport to specific structure (Hongpaisan et al. (2013) . The present study, however, focused on the structure changes and we therefore used immunohistochemistry to confirm the morphological studies: EM (see below) and confocal microscopy of DiI staining. with control data being set at 100%.
Quantification for immunostained density of pre-or postsynaptic structure
Confocal images of the density of postsynaptic dendritic spines, presynaptic axonal terminals, postsynaptic membranes, or presynaptic membranes per 45 x 45 x 0.6 μ m 3 volume of the CA1 stratum radiatum were analyzed as previously described (Hongpaisan et al., 2011) .
Electron microscopy
Under anesthesia with pentobarbiturate, mice were perfused through the heart with PBS (5 ml) and 2% glutaraldehyde and 3% paraformaldehyde in PBS (80 ml). Brains were removed and stored in fixative at 4°C. Hippocampal slices were processed for Epon-embedding, resectioned to 90 nm thickness, collected on a grid, and stained with uranyl acetate and lead citrate. Electron micrographs were taken of the middle of each section with a JEOL 1010 transmission electron microscope. Random sampling was achieved by orienting the hippocampal CA1 area under lowpower magnification. The random area that immediately appeared after switching to a higher magnification (7,000X magnification) was imaged with a CCD camera. Electron micrographs 
Spatial learning and memory and visible platform test
A modified Morris water-maze task (2 trials/day for 8 days), a difficult task for revealing mild impairments, was used to evaluate spatial learning and memory.
Water maze training sessions began on the 9th day after the last dose of bryostatin-1, a time gap to separate potential acute effects from the chronic therapeutic impacts. The maze pool had a diameter of 114 cm and height of 60 cm and was filled with 40 cm H 2 O (22±1°C), mixed with
The sensorimotor ability of mice was evaluated with a visible platform test. The platform was placed at a new location and was marked with a pole that protruded 9 inches above the water surface.
Statistical analysis was performed using the analysis of variance (ANOVA), followed by Figure 1A ,B) were observed. In wild-type mice, bryostain-1 significantly increased postsynaptic membranes (P<0.01; Figure 1B ). Fragile X mice showed significant decreases in the densities of postsynaptic membranes (P<0.05; Figure 1B ). Bryostatin-1 improved the formation of postsynaptic membranes (P<0.001; Figure 1B ) in fragile X mice. The data using immunohistochemistry confirmed the results from electron microscopy (see below).
Accumulation of mGluR5 into postsynaptic densities was examined with the colocalization of mGluR5 and PSD-95, using immunohistochemistry and confocal microscopy ( Figure 1A ).
Significant differences among wild-type mice (WC), wild-type mice with bryostatin-1 (WB), fragile X mice (TC), and fragile X mice with bryostatin-1 (TB) groups were observed for the density of mGluR5-containing postsynaptic membranes (colocalization area of mGluR5 and PSD-95; ANOVA, F 1,187 =7.814, P<0.001; Figure 1C ) and mGluR5 level in postsynaptic membranes (mGluR5 fluorescence intensity in the colocalization area; F 1,187 =3.478, P<0.01; Figure 1D ). Data with significant difference with ANOVA were subsequently analyzed with two-tailed paired T-test. Bryostatin-1 had no effect in wild-type mice, whereas in transgenic mice, decreases in the number of mGluR5-containing postsynaptic membranes (P<0.01; Figure   1C ) and their mGluR5 level (P<0.05; Figure 1D ) were significantly improved with bryostatin-1 (P<0.01; Figure 
Bryostatin-1 prevents the Loss of Brain-Derived Neurotrophic Factor in young fragile X mice
Immunohistochemistry of BDNF in the CA1 stratum radiatum, imaged with a confocal microscope, showed a significant difference among experimental groups (F 1,120 =27.484, Figure 1E ). Bryostatin-1 did not increase BDNF expression in wild-type mice ( Figure   1F ). However, Figure 1E showed that in transgenic mice, the reduction of BDNF (P<0.001) was significantly improved (P<0.001) and even elevated above wildtype levels (compared TB with WC; P<0.05) with bryostatin-1.
P<0.001;
Bryostatin-1 Increases Presynaptic Vesicle Concentration within Presynaptic Boutons
Densities of presynaptic axonal boutons and their presynaptic vesicle content in the hippocampal CA1 stratum radiatum were evaluated with confocal immunohistochemistry ( Figure 2A ). ANOVA showed no significant difference among experimental groups for presynaptic axonal bouton density, as determined by counting the grains of presynaptic vesicle protein synaptophysin ( Figure 2B ). However, significant differences among experiment groups were seen for presynaptic vesicle concentration within the presynaptic axonal boutons, as determined with the fluorescent intensity of synaptophysin (F 3,142 =2.726, P<0.05; Figure 2C ).
Although bryostatin-1 had no effect on presynaptic bouton density in all experimental conditions ( Figure 2B ), bryostatin-1 increased presynaptic vesicle concentration within the presynaptic boutons both in wild-type (P<0.05) and fragile X (P<0.01) mice ( Figure 2C ).
This article has not been copyedited and formatted. The final version may differ from this version. Electron microscopy was further used to determine the concentration of presynaptic vesicles at a single axonal bouton level ( Figure 2E ). There was a significant difference among experimental groups (F 3,190 =8.018, P<0.001; Figure 2D ). Electron microscopy confirmed the results of confocal immunohistochemistry that no significant change in presynaptic vesicles level was observed in the fragile X mice ( Figure 2D , compared TC with WC), and bryostyatin-1 significantly increased presynaptic vesicle level in both wild-type and fragile X mice ( Figure 2D , WB vs. WC, and TB vs. TC).
Bryostatin-1 Increases Synaptic Densities
Density of axodendritic synapses in the hippocampal CA1 stratum radiatum was determined with electron microscopy ( Figure 3A ). There was a significant difference among experimental groups (F 3,195 =6.426, P<0.001; Figure 3B ). In wild-type mice, bryostatin-1 significantly increased synaptic density (P<0.05; Figure 3B ). In fragile X mice, synaptic loss (P<0.05) was significantly reversed (P<0.001) with bryostatin-1 treatment ( Figure 3B ).
Changes in presynaptic membranes in the hippocampal CA1 stratum radiatum were further studied, using confocal immunohistochemistry ( Figure 3C ). Significant differences among experiment groups for growth-associated protein 43 (GAP-43), predominantly located in presynaptic membranes (F 3, 117 =13.149, P<0.001; Figure 3D ), were observed. In wild-type mice, bryostain-1 significantly increased presynaptic membranes (P<0.05; Figure 3D ). Fragile X mice showed significant decreases in the densities of presynaptic membranes (P<0.001; Figure 3D ).
Bryostatin-1 improved the formation of presynaptic membranes (P<0.05; Figure 3D ). The data using immunohistochemistry confirmed the results from electron microscopy (see below).
This article has not been copyedited and formatted. The final version may differ from this version. In the wild-type mice, bryostatin-1 increased the synaptic density ( Figure 3A -E), but not the dendritic spine density ( Figure 3I ,K), suggesting that some dendritic spines form more than one synapse.
Bryostatin-1 Increases Mushroom-Shape Dendritic Spine Formation
Change of the dendritic spine number at a single apical dendrite level in the hippocampal CA1 pyramidal neuron was studied with DiI staining and imaged with a confocal microscopy ( Figure 3E ). A significant difference among experimental groups for mushroom dendritic spines was seen (F 3,142 =7.186, P<0.001; Figure 3F ).
In wild-type mice, bryostatin-1 significantly elevated the number of mushroom spines per 100 μm dendritic shaft above wild-type levels (P<0.05; Figure 3F , compared WB with WC), correlated with the enhancement of memory retention after water maze training. In the fragile X mice, a significant decrease in mushroom dendritic spines (P<0.01; Figure 3F , compared TC with WC) was significantly improved with bryostatin-1 treatment (P<0.001; Figure 3F , compared TB with TC). The number of mushroom spines in fragile X mice treated with bryostatin-1 was not different from that in wild-type mice treated with bryostatin-1 ( Figure 3F , compared TB with WB).
Bryostatin-1 Improves the Maturation of Dendritic Spines in young fragile X Mice
Significance differences among experimental groups were found for immature spines or filopodia (F 3,142 =24.386, P<0.001; Figure 3G ) and mature dendritic spines (mushroom+thin+stubby spines; F 3,142 =3.956, P<0.01; Figure 3H ) were seen at a single apical dendritic shaft of the CA1 pyramidal neuron. In wild-type mice, bryostatin-1 treatment did not change the numbers of filopodia and mature dendritic spines ( Figure 3G ,H). In the fragile X mice, an increased number of immature spines (P<0.001; Figure 2H ) and a decreased number of mushroom+thin+stubby spines (P<0.05; Figure 3H ) were observed compared to wild-type mice.
These changes were reversed to the wild-type control level with bryostatin-1 treatment.
Changes in overall dendritic spine density (45 x 45 x 0.6 μ m 3 volume of stratum radiatum), a hippocampal part that correlated to the apical dendrites of CA1 pyramidal neurons, were studied with immunohistochemistry of the dendritic spine-specific protein spinophilin ( Figure 3I ). A significant difference among experiment groups was seen (F 3, 154 =4.748, P<0.01). Bryostatin-1 had no effect on dendritic spine density in wild-type mice but improved the loss of dendritic spine density in the fragile X mice (P<0.05; Figure 3J ). These data on the densities of dendritic spines per brain volume units were correlated with changes in the number of dendritic spines on dendritic spine shafts studied with DiI staining (compared Figure 3G with 3H).
Taken together, the results suggest that bryostatin-1 improves the maturation of dendritic spines from the immature spines in the young fragile X mice.
Bryostatin-1 prevents deficits in spatial learning and memory of young fragile X mice but did not alter sensorimotor ability
There were significant learning differences among the 4 groups (F 3,560 =58.528, P<0.001; 1 vs fragile X mice with bryostatin-1: F 1,272 =0.669, P>0.05), indicating that the chronic bryostatin-1 treatment not only improved spatial learning in the wild-type mice but also repaired the learning deficits of the fragile X mice when tested at an adult age after an early 6-week treatment.
The results in the probe test ( Figure 4B -E) were analyzed using target quadrant ratio (dividing the target quadrant distance by the average of the non-target quadrant values during the probe test; Figure 4F ). There were significant differences in the target quadrant ratio among the groups (F 3,38 =8.790, P<0.001), indicating differences in the spatial memory among the groups. A visible platform test, determined after the probe test reveals no significant differences among the groups (F 3,35 =0.179 P>0.05; Figure 4G ), indicating that there were no significant group differences in sensorimotor ability and escape motivation of the mice among different groups, so that the differences in the learning and memory-recall performance among the groups cannot be attributed to the differences in their sensorimotor ability and escape motivation. involve a loss of some dendritic channels (Routh et al., 2013) , but can be rescued with chronic bryostatin-1 treatment at a young age, as shown in the present study, and previously in adults (Sun et al., 2014) . The treatment in the present study began at least 1 month earlier than our previous study (Sun et al., 2014) , in which the same dose was administered at an adult age (2 months of age) for a longer treatment period (13 weeks). Histological analyses were all performed at an adult age. Earlier treatment may lead to more favorable outcomes due to several reasons. First, the therapeutic outcomes appear significantly better in the early-onset treatment group with the same doses of treatment, including the higher enhancement of BDNF expression and mushroom-shaped dendritic spine formation ( Figure 5A find no difference in mGluR5 protein expression (Dolen et al., 2007) , while a reduction was observed in the detergent insoluble fraction of synaptic membranes isolated from the forebrain of fragile X mice (Giuffrida et al., 2005) . There are also some observations of reduced expression of mGluR5 in fragile X mice (Giuffrida et al., 2005) , but no difference in mGluR5 expression in total hippocampal homogenates has been reported by others (Huber et al., 2002) . The no differences in mGluR5 expression (Huber et al., 2002; Giuffrida et al., 2005) between fragile X mice and control but reduced association of mGluR5 with PSD in fragile X mice might suggest an increased non-PSD association of mGluR5 labeling in fragile X mice. However, the evidence that supports the notion that mGluR5 overactivity reflects neuronal pathology in FXS seems very solid. Reducing mGluR5 expression or mGluR5 inhibitors have been shown to correct a broad range of fragile X phenotypes in fragile X mice (Huber et al., 2002; Hajós, 2014) . Although one would expect an increased colocalization of postsynaptic mGluR5 when it is overactive, our study does not rule out the possibility that the observed reduction in mGluR5 labeling in the fragile X mice might partially reflect the reduced PSD labeling in the brain area. Nevertheless, our results indicate that the desired therapeutic effects can be achieved in the fragile X mice Consistent with our previous study in the fragile X mice, chronic bryostatin-1 rescues other FXS phenotypes, such as PSD-95 (Zalfa et al., 2007; Tang and Alger, 2015) and BDNF levels in the hippocampus. PSD-95, a major synapse organizer, plays an important role in the stabilization of spines and synapses and in activity-regulated formation of PSD. BDNF is important for local protein synthesis and synaptic plasticity (Neumann et al., 2015) . Although images of the BDNF fluorescence labeling were used to measure the BDNF levels in this study, the labeling intensity was found to reliably reflect the BDNF levels in the same brain areas determined with an immunochemical assay, such as an ELISA assay, in our previous studies (Sun et al., 2004) .
Reduction of BDNF expression in fragile X mice induces cognitive deficits (Louhivuori et al., 2011; Uutela et al., 2012) . Infusion of BDNF has been found to restore synaptic function in slices from fragile X mice (Lauterborn et al., 2007) . The decrease in BDNF accumulation in the CA1 stratum radiatum was significantly prevented with both the early-onset (the present study) and late-onset (Sun et al., 2014) bryostatin-1 treatment. However, early-onset bryostatin-1 treatment, but not late-onset bryostatin-1 treatment, also enhanced the BDNF level (higher than the control wild-type without bryostatin-1 treatment).
It is interesting that in the wild-type mice, the early-onset bryostatin-1 treatment significantly elevated the spatial memory retention (in the present study) above wild-type levels, whereas the late-onset bryostatin-1 treatment did not enhance memory retention (Sun et al., 2014) , with the same lag period to separate acute impact from the chronic therapeutic effects. However, we did not find a significant enhancement of PKCε-induced BDNF levels after early-onset bryostatin-1 treatment. This might implicate that other PKCε-dependent pathways might also be involved in synaptic plasticity. The direct interaction of PKCε with actin is important for synaptic function and neurite growth and synaptic formation (Prekeris et al., 1996) . PKCε may also induce Bryostatin-1, a highly potent and relatively specific PKCε activator, with pharmacological profiles of synaptogenesis and synaptic maturation/repairing (Hongpaisan and Alkon, 2007 Alkon, , 2011 Sun et al., 2015) , rescues synaptic and memory functions and other phenotypic features in young fragile X mice. At low concentrations (about 1 nm), its PKC activation is mostly on PKCε, and less on PKCα. At higher concentrations, however, activities of other PKC isoforms might also be affected. At a lower dose (10 μ g/m 2 , 2 doses/week for 3 weeks), bryostatin-1 alone was found to have no significant effects on spatial learning and memory in rats (Sun and Alkon, 2008) . We previously observed that its chronic administration did not alter swimming speed of rodents in the swimming test (Sun and Alkon, 2008) . Evidence is accumulating, supporting an essential role of some PKC isoforms in various phases and types of learning and memory (Alkon et al., 2005 (Alkon et al., , 2007 . Bryostatin-1-like agents enhance the synthesis of proteins required for memory processing and synaptic repair/synaptogenesis, reduce Aβ formation through activation of α -secretase and increase Aβ degradation via the endothelin-converting enzyme, and are antiapoptotic. Since intellectual ability, as well as retardation (Wang et al., 2012) , involves multiple players in signal processing, these agents, for their multi-targeting actions (Sun et al., 2015) , may represent a more effective class of therapeutics than agents that target a single factor in this complex pathologic process (Vislay et al., 2013) .
This article has not been copyedited and formatted. The final version may differ from this version. presynaptic vesicles within the axonal boutons, based on (E) electron microscopy at higher magnification. White arrows, presynaptic vesicles; red arrow, synapses; yellow highlighted, dendritic spines. WC, wild-type with vehicle; WB, wild-type with bryostatin-1; TC, fragile X mice with vehicle; TB, fragile X mice with bryostatin-1. Data are shown as means ± S.E.M, n = 40-55 random CA1 stratum radiatum areas from 4 mice per experimental conditions. All the images are from the stratum radiatum only. *: P < 0.05, **: P < 0.01, ***: P < 0.001. shafts or n = 40 random CA1 stratum radiatum areas from 4 mice per experimental conditions from 4 mice per experimental conditions. All the images are from the stratum radiatum only. *: P < 0.05; **: P < 0.01; ***: P < 0.001. 
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